<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PCOMPBIOL-D-11-00866</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1002189</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Computational biology</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Chemistry</subject>
          <subj-group>
            <subject>Computational chemistry</subject>
          </subj-group>
          <subj-group>
            <subject>Medicinal chemistry</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Computer science</subject>
          <subj-group>
            <subject>Computer modeling</subject>
          </subj-group>
          <subj-group>
            <subject>Computerized simulations</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Physics</subject>
          <subj-group>
            <subject>Biophysics</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Chemistry</subject>
          <subject>Computational Biology</subject>
          <subject>Computer Science</subject>
          <subject>Physics</subject>
        </subj-group>
      </article-categories><title-group><article-title>Identification of Potent EGFR Inhibitors from TCM Database@Taiwan</article-title><alt-title alt-title-type="running-head">Potent EGFR Inhibitors from TCM Database@Taiwan</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Yang</surname>
            <given-names>Shun-Chieh</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Chang</surname>
            <given-names>Su-Sen</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Chen</surname>
            <given-names>Hsin-Yi</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Chen</surname>
            <given-names>Calvin Yu-Chian</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1"><label>1</label><addr-line>Laboratory of Computational and Systems Biology, School of Chinese Medicine, China Medical University, Taichung, Taiwan</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Department of Bioinformatics, Asia University, Taichung, Taiwan</addr-line>       </aff><aff id="aff3"><label>3</label><addr-line>China Medical University Beigang Hospital, Yunlin, Taiwan</addr-line>       </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Briggs</surname>
            <given-names>James M.</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">University of Houston, United States of America</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">ycc929@MIT.EDU</email>, <email xlink:type="simple">ycc@mail.cmu.edu.tw</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: CYCC. Performed the experiments: SCY HYC CYCC. Analyzed the data: SCY SSC. Contributed reagents/materials/analysis tools: HYC CYCC. Wrote the paper: SCY SSC CYCC.</p>
        </fn>
      <fn fn-type="conflict">
        <p>The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <month>10</month>
        <year>2011</year>
      </pub-date><pub-date pub-type="epub">
        <day>13</day>
        <month>10</month>
        <year>2011</year>
      </pub-date><volume>7</volume><issue>10</issue><elocation-id>e1002189</elocation-id><history>
        <date date-type="received">
          <day>14</day>
          <month>6</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>7</month>
          <year>2011</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Yang et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
        <p>Overexpression of epidermal growth factor receptor (EGFR) has been associated with cancer. Targeted inhibition of the EGFR pathway has been shown to limit proliferation of cancerous cells. Hence, we employed Traditional Chinese Medicine Database (TCM <email xlink:type="simple">Database@Taiwan</email>) (<ext-link ext-link-type="uri" xlink:href="http://tcm.cmu.edu.tw" xlink:type="simple">http://tcm.cmu.edu.tw</ext-link>) to identify potential EGFR inhibitor. Multiple Linear Regression (MLR), Support Vector Machine (SVM), Comparative Molecular Field Analysis (CoMFA), and Comparative Molecular Similarities Indices Analysis (CoMSIA) models were generated using a training set of EGFR ligands of known inhibitory activities. The top four TCM candidates based on DockScore were 2-O-caffeoyl tartaric acid, Emitine, Rosmaricine, and 2-O-feruloyl tartaric acid, and all had higher binding affinities than the control Iressa®. The TCM candidates had interactions with Asp855, Lys716, and Lys728, all which are residues of the protein kinase binding site. Validated MLR (r<sup>2</sup> = 0.7858) and SVM (r<sup>2</sup> = 0.8754) models predicted good bioactivity for the TCM candidates. In addition, the TCM candidates contoured well to the 3D-Quantitative Structure-Activity Relationship (3D-QSAR) map derived from the CoMFA (q<sup>2</sup> = 0.721, r<sup>2</sup> = 0.986) and CoMSIA (q<sup>2</sup> = 0.662, r<sup>2</sup> = 0.988) models. The steric field, hydrophobic field, and H-bond of the 3D-QSAR map were well matched by each TCM candidate. Molecular docking indicated that all TCM candidates formed H-bonds within the EGFR protein kinase domain. Based on the different structures, H-bonds were formed at either Asp855 or Lys716/Lys728. The compounds remained stable throughout molecular dynamics (MD) simulation. Based on the results of this study, 2-O-caffeoyl tartaric acid, Emitine, Rosmaricine, and 2-O-feruloyl tartaric acid are suggested to be potential EGFR inhibitors.</p>
      </abstract><abstract abstract-type="summary">
        <title>Author Summary</title>
        <p>Tumor growth is associated with overexpression of epidermal growth factors receptors. Targeted control of EGFR by EGFR inhibitors is an attractive therapy alternative to conventional cancer treatment that offers specificity and reduced adverse effects. The purpose of this study was to identify natural compounds from traditional Chinese medicine that may be used as EGFR inhibitors. The top four TCM compounds with the highest binding affinity to EGFR were selected and their suitability as EGFR inhibitors confirmed with different statistical prediction models. The candidate compounds had higher bioactivity than Iressa®, the drug that is clinically used. The TCM compounds also met key structural components that were characteristic among known inhibitors. In addition, the binding between TCM compounds and EGFR were stable which is a fundamental requirement for any targeting drug. Results from bioactivity prediction, structural component matching, and binding stability all point to the possibility of these TCM compounds as suitable EGFR inhibitor candidates.</p>
      </abstract><funding-group><funding-statement>The research was supported by grants from the National Science Council of Taiwan (NSC 99-2221-E-039-013-), Committee on Chinese Medicine and Pharmacy (CCMP100-RD-030), China Medical University and Asia University (CMU98-TCM, CMU99-TCM, CMU99-S-02, CMU99-ASIA-25, CMU99-ASIA-26 CMU99-ASIA-27 CMU99-ASIA-28). This study is also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH100-TD-B-111-004) and Taiwan Department of Health Cancer Research Center of Excellence (DOH100-TD-C-111-005). We are grateful to the Asia University cloud-computing facilities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
        <page-count count="10"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Target-specific therapies have generated much attention in addition to conventional cancer treatments <xref ref-type="bibr" rid="pcbi.1002189-deOliveira1">[1]</xref>–<xref ref-type="bibr" rid="pcbi.1002189-Wang1">[3]</xref>. By targeting key molecules essential for cellular function, replication, or tumorigenesis, such therapies may exert cytostatic or cytotoxic effects on tumors while minimizing nonspecific toxicities associated with chemotherapy or irradiation <xref ref-type="bibr" rid="pcbi.1002189-Herbst1">[4]</xref>.</p>
      <p>The epidermal growth factor receptor (EGFR) signaling pathway is one of the most important pathways in mammalian cells <xref ref-type="bibr" rid="pcbi.1002189-Oda1">[5]</xref>. Specific ligands, such as epidermal growth factor (EGF) and transforming growth factor alpha (TGFα), bind and activate EGFR, triggering autophosphorylation of the intracytoplasmic EGFR tyrosine kinase domain <xref ref-type="bibr" rid="pcbi.1002189-Franklin1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1002189-Linggi1">[7]</xref>. The phosphorylated tyrosine kinase residues serve as binding sites for signal transducers and activators of intracellular substrates, which then stimulate intracellular signal transduction cascades that upregulate biological processes such as gene expression, proliferation, angiogenesis, and inhibition of apoptosis <xref ref-type="bibr" rid="pcbi.1002189-Chan1">[8]</xref>. EGFR overexpression has been shown to activate downstream signaling pathways, resulting in cells that have aggressive growth and invasive characteristics <xref ref-type="bibr" rid="pcbi.1002189-Either1">[9]</xref>. Tumor cell motility, adhesion, metastasis, and angiogenesis have also been associated with stimulated EGFR pathways <xref ref-type="bibr" rid="pcbi.1002189-Shibata1">[10]</xref>–<xref ref-type="bibr" rid="pcbi.1002189-Mitsudomi1">[12]</xref>. Since EGFR over-expression often differentiates tumor cells from normal cells, it is possible for EGFR inhibitory molecules to act on tumor cells and attenuate their proliferation rates <xref ref-type="bibr" rid="pcbi.1002189-Herbst1">[4]</xref>.</p>
      <p>Several tyrosine kinase inhibitors were approved for clinical use. Iressa® (gefitinib) is highly selective for EGFR tyrosine kinase and is commonly used for treating lung cancer <xref ref-type="bibr" rid="pcbi.1002189-Sordella1">[13]</xref>. EGFR downstream signaling is competitively inhibited by Iressa® at its ATP binding site <xref ref-type="bibr" rid="pcbi.1002189-Wakeling1">[14]</xref>. Other therapeutic agents with inhibitory mechanisms similar to Iressa® include Erlotinib (Tarceva®) against non-small cell lung cancer (NSCLC) and pancreatic cancer <xref ref-type="bibr" rid="pcbi.1002189-Merlo1">[15]</xref>, <xref ref-type="bibr" rid="pcbi.1002189-VandenEynde1">[16]</xref>, and Vandetanib (Zactima®) against late stage medullary thyroid cancer <xref ref-type="bibr" rid="pcbi.1002189-Sherman1">[17]</xref>. Lapatinib (Tykerb®) is a dual inhibitor of EGFR and HER2 tyrosine kinases approved for metastatic breast cancer <xref ref-type="bibr" rid="pcbi.1002189-Medina1">[18]</xref>, <xref ref-type="bibr" rid="pcbi.1002189-Johnston1">[19]</xref>. Though the effect of Iressa® on lung cancer has been well established, severe side effects has also been reported <xref ref-type="bibr" rid="pcbi.1002189-Forsythe1">[20]</xref>. Adverse reactions listed under Iressa® product information include diarrhea, skin rash and dryness, nausea, vomiting, haemorrhage, anorexia, asthenia, and in some cases, interstitial lung disease with fatal outcomes <xref ref-type="bibr" rid="pcbi.1002189-AustraZeneca1">[21]</xref>. The adverse effects of available treatments necessitate continuous search efforts for alternatives with less toxicity.</p>
      <p>Computational predictions in biology and biomedicine are of significant importance for generating useful data which otherwise be time-consuming and costly through experiments alone <xref ref-type="bibr" rid="pcbi.1002189-Wang1">[3]</xref>, <xref ref-type="bibr" rid="pcbi.1002189-Chen1">[22]</xref>–<xref ref-type="bibr" rid="pcbi.1002189-Chou3">[27]</xref>. Computational predictions, combined with information derived from structural bioinformatics analysis, can provide useful insights and timely information for both basic research and drug development <xref ref-type="bibr" rid="pcbi.1002189-Chou4">[28]</xref>, <xref ref-type="bibr" rid="pcbi.1002189-Chou5">[29]</xref>. Much cutting-edge cancer drug development has been conducted through the use of computational bioinformatics and modeling <xref ref-type="bibr" rid="pcbi.1002189-Liao1">[30]</xref>–<xref ref-type="bibr" rid="pcbi.1002189-Nandi1">[37]</xref>. The powerful ability of modern computational prediction and bioinformatics were adopted in this research to search for novel EGFR inhibitors.</p>
      <p>Traditional Chinese medicines (TCM) are natural substances with therapeutic effects on many diseases <xref ref-type="bibr" rid="pcbi.1002189-Cheng1">[38]</xref>–<xref ref-type="bibr" rid="pcbi.1002189-Hsu1">[40]</xref>. The vast number of TCM represents a rich resource that can be explored for drug development. We had investigated kinase inhibitor candidates from TCM targeting HER2 and HSP90 receptors before <xref ref-type="bibr" rid="pcbi.1002189-Chou4">[28]</xref>, <xref ref-type="bibr" rid="pcbi.1002189-Huang2">[41]</xref>–<xref ref-type="bibr" rid="pcbi.1002189-Chen2">[42]</xref>. Though EGFR kinase inhibitors have been investigated through different screening and modeling scenarios <xref ref-type="bibr" rid="pcbi.1002189-Choowongkomon1">[43]</xref>–<xref ref-type="bibr" rid="pcbi.1002189-Konkimalla1">[47]</xref>, none from TCM compounds has been reported to date. This study utilized the world’s largest TCM <email xlink:type="simple">Database@Taiwan</email> <xref ref-type="bibr" rid="pcbi.1002189-Chen3">[48]</xref> to screen for potential EGFR inhibitors from TCM compounds and applied structure- and ligand-based methods to evaluate the suitability of candidates as EGFR inhibitors.</p>
    </sec>
    <sec id="s2" sec-type="materials|methods">
      <title>Materials and Methods</title>
      <p>A useful predictor for a biological system should include the following steps <xref ref-type="bibr" rid="pcbi.1002189-Chou6">[49]</xref>: (i) selection of a valid dataset to train and test the predictor; (ii) formulate samples with an effective mathematical expression that reflects intrinsic correlation with the attribute to be predicted; (iii) develop a powerful algorithm to operate the prediction; (iv) objectively evaluate accuracy of the predictor through cross-validation tests. The experimental design of the current study follows these guidelines and details are explained in the following sections.</p>
      <sec id="s2a">
        <title>EGFR Protein Sequence, Structure, and Characteristics</title>
        <p>The EGFR protein sequence (EGFR_HUMAN, P00533) used in this study was obtained from Swiss-Prot <xref ref-type="bibr" rid="pcbi.1002189-TheUniProt1">[50]</xref>, and the 3D structure (PDB: 2ITY) <xref ref-type="bibr" rid="pcbi.1002189-Yun1">[51]</xref> used for analyses was downloaded from Protein Data Bank. The tyrosine kinase was encoded from Phe712-Leu979, and the ATP binding site was located at Leu718–Val726.</p>
      </sec>
      <sec id="s2b">
        <title>Candidate Screening and Docking Studies</title>
        <p>The Traditional Chinese Medicine (TCM <email xlink:type="simple">Database@Taiwan</email>) database (<ext-link ext-link-type="uri" xlink:href="http://tcm.cmu.edu.tw" xlink:type="simple">http://tcm.cmu.edu.tw</ext-link>) was used to screen for potential EGFR inhibitors from more than 20,000 compounds within the database. All compounds were operated using the Prepare Ligands module with Lipinski’s rule of five using Discovery Studio 2.5 (DS 2.5; Accelrys Inc., San Diego, CA). Iressa® was selected as the control. The LigandFit program (DS 2.5) was used to locate the best docking pose for different confirmations under the Chemistry at HARvard Macromolecular Mechanics (CHARMm) force field <xref ref-type="bibr" rid="pcbi.1002189-Brooks1">[52]</xref>. Results for the docking studies were ranked according to Dock Score.</p>
      </sec>
      <sec id="s2c">
        <title>Descriptor Generation Using Genetic Function Approximation (GFA) Algorithm</title>
        <p>Twenty ligands with demonstrated inhibition against EGFR were used in this study (<xref ref-type="supplementary-material" rid="pcbi.1002189.s001">Table S1</xref>) <xref ref-type="bibr" rid="pcbi.1002189-Fidanze1">[53]</xref>. Descriptors for each ligand were identified using the Calculate Molecular Properties program in DS 2.5. Predictive models containing five optimum descriptors were generated using the Genetic Function Approximation (GFA) algorithm. Descriptors in the model with the highest r<sup>2</sup> value were used to construct ligand activity prediction models.</p>
      </sec>
      <sec id="s24">
        <title>Ligand Activity Predictions Using Multiple Linear Regression (MLR) and Support Vector Machines (SVM)</title>
        <p>A MLR model using the descriptors from the top GFA algorithm was constructed using Matlab Statistics Toolbox (MathWorks, Natick, MA) and validated using MLR Leave-One-Out validation <xref ref-type="bibr" rid="pcbi.1002189-Picard1">[54]</xref>. The MLR model was trained with 17 randomly selected ligands with EGFR inhibitory activity (<xref ref-type="supplementary-material" rid="pcbi.1002189.s001">Table S1</xref>) and used to predict the activity (pIC<sub>50</sub>) of the control and TCM candidates.</p>
        <p>The identical descriptors were normalized to the range of [−1,+1] and plugged into the libSVM program to generate a SVM prediction model<xref ref-type="bibr" rid="pcbi.1002189-Fan1">[55]</xref>. Following model training with the 17-ligand training set, the SVM model was used to predict the activity of the control and TCM candidates.</p>
      </sec>
      <sec id="s25">
        <title>3D Quantitative Structure-Activity Relationship (QSAR) Model</title>
        <p>Ligands used in the previous sections were also used for 3D-QSAR analysis. The 2-dimensional (2D) and 3-dimensional (3D) ligand structures were drawn with ChemBioOffice 2008 (PerkinElmer Inc., Cambridge, MA) under a Molecular Mechanics 2 (MM2) force field. Following ligand alignment, Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarities Indices Analysis (CoMSIA) models were constructed using partial least squares statistical method (PLS). Cross-Validated (CV) correlation coefficient (q<sup>2</sup>) and non-cross-validation correlation coefficient (r<sup>2</sup>) were used to validate the models. Biological activities of Iressa® and TCM candidate compounds were predicted using the generated 3D-QSAR contour map.</p>
      </sec>
      <sec id="s26">
        <title>Molecular Dynamics Simulation</title>
        <p>Molecular dynamics (MD) of Iressa® and the TCM candidates were simulated using DS2.5 Standard Dynamics Cascade and Dynamics package. Sample preparation was conducted under the following parameters: [minimization] steepest descent and conjugate gradient: each with maximum steps of 500, [heating time] 50 ps, [equilibration time] 200 ps. The simulations were produced with a total production time of 20 ns with NVT, constant temperature dynamics of Berendsen weak coupling method, a temperature decay time of 0.4 ps, and a target temperature of 310K. Root mean square deviations (RMSD) of protein-ligand complex and individual ligands, total energy of protein-ligand complex, hydrogen bond (H-bond), and H-bond distance were analyzed using the Analyze Trajectory function following MD simulation.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results/Discussion</title>
      <sec id="s3a">
        <title>Candidate Screening and Docking Studies</title>
        <p>The top four TCM candidates with the highest Dock Score were 2-O-caffeoyl tartaric acid, Emitine, Rosmaricine, and 2-O-feruloyl tartaric acid (<xref ref-type="table" rid="pcbi-1002189-t001">Table 1</xref>). Corresponding scaffolds of the top TCM candidates are illustrated in <xref ref-type="fig" rid="pcbi-1002189-g001">Figure 1</xref>. Iressa®, Emitine, and Rosmaricine had amine groups available for H bonding whereas 2-O-Caffeoyl tartaric acid and 2-O-feruloyl tartaric acid had carbonyl groups. The different residues available for H bonding resulted in different binding poses (<xref ref-type="fig" rid="pcbi-1002189-g002">Figure 2</xref>). Binding of Iressa® (<xref ref-type="fig" rid="pcbi-1002189-g002">Figure 2a</xref>), Emitine (<xref ref-type="fig" rid="pcbi-1002189-g002">Figure 2c</xref>), and Rosmaricine (<xref ref-type="fig" rid="pcbi-1002189-g002">Figure 2e</xref>) to tyrosine kinase were located within the pocket, with H-bonds formed between the amine group of the ligand compounds and the carboxyl group of Asp855. 2-O-Caffeoyl tartaric acid (<xref ref-type="fig" rid="pcbi-1002189-g002">Figure 2b</xref>) and 2-O-feruloyl tartaric acid (<xref ref-type="fig" rid="pcbi-1002189-g002">Figure 2e</xref>) docked outside the tyrosine kinase pocket and formed multiple H-bonds through their carboxyl groups with Lys716 and Lys728. The binding location of 2-O-caffeoyl tartaric acid and 2-O-feruloyl tartaric acid directly blocks the ATP binding site of tyrosine kinase located from Leu718–Val726. Dock scores of each TCM candidate is given in <xref ref-type="table" rid="pcbi-1002189-t001">Table 1</xref>. All candidates have higher dock scores than Iressa®, indicating higher binding affinities to the tyrosine kinase receptor than Iressa®.</p>
        <fig id="pcbi-1002189-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002189.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Scaffolds of the control and TCM compounds.</title>
            <p>(A) Iressa, (B) 2-O-Caffeoyl tartaric acid, (C) Emetine, (D) Rosmaricine, and (E) 2-O-Feruloyl tartaric acid.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.g001" xlink:type="simple"/>
        </fig>
        <fig id="pcbi-1002189-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002189.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Docking pose of different compounds in EGFR using LigandFit.</title>
            <p>(A) Iressa, (B) 2-O-Caffeoyl tartaric acid, (C) Emetine, (D) Rosmaricine, and (E) 2-O-Feruloyl tartaric acid. Binding site amino acids are shown in red (negatively charged amino acids) and blue (positively charged amino acids). Hydrogen bonds are color coded based on bond distance: 1.6–1.8Å (orange), 1.8–2.0Å (yellow), 2.0–2.2Å (light green), 2.2–2.4Å (neon green), and 2.4–2.5Å (dark green).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.g002" xlink:type="simple"/>
        </fig>
        <table-wrap id="pcbi-1002189-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1002189.t001</object-id><label>Table 1</label><caption>
            <title>Docking score and biological activity predictions of top TCM candidates in comparison with the control.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1002189-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.t001" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="2" rowspan="1">Predicted Activity (pIC<sub>50</sub>)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Compounds</td>
                <td align="left" colspan="1" rowspan="1">Dock Score</td>
                <td align="left" colspan="1" rowspan="1">MLR</td>
                <td align="left" colspan="1" rowspan="1">SVM</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">2-O-Caffeoyl tartaric acid</td>
                <td align="left" colspan="1" rowspan="1">118.065</td>
                <td align="left" colspan="1" rowspan="1">8.386</td>
                <td align="left" colspan="1" rowspan="1">7.041</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Emetine</td>
                <td align="left" colspan="1" rowspan="1">113.424</td>
                <td align="left" colspan="1" rowspan="1">5.548</td>
                <td align="left" colspan="1" rowspan="1">7.140</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Rosmaricine</td>
                <td align="left" colspan="1" rowspan="1">105.149</td>
                <td align="left" colspan="1" rowspan="1">4.543</td>
                <td align="left" colspan="1" rowspan="1">7.463</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">2-O-Feruloyl tartaric acid</td>
                <td align="left" colspan="1" rowspan="1">104.284</td>
                <td align="left" colspan="1" rowspan="1">8.359</td>
                <td align="left" colspan="1" rowspan="1">7.242</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Iressa<xref ref-type="table-fn" rid="nt101">*</xref></td>
                <td align="left" colspan="1" rowspan="1">60.791</td>
                <td align="left" colspan="1" rowspan="1">6.715</td>
                <td align="left" colspan="1" rowspan="1">5.110</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt101">
              <label/>
              <p>*control.</p>
            </fn>
          </table-wrap-foot></table-wrap>
      </sec>
      <sec id="s3b">
        <title>Ligand Activity Predictions Using MLR and SVM</title>
        <p>Representative descriptors from the top GFA algorithm include: Num_H_Acceptors_Lipinski (equivalent of N+O count), Molecular_SurfaceArea (the total surface area for each molecule using a 2D approximation), Kappa_1 (Kappa Shape Indices), PMI_Y (principle moment of inertia Y-component), and Shadow Xlength (length of molecule in the X dimension). The descriptors were validated using Leave-One-Out method which is the most objective of all available cross-validation methods <xref ref-type="bibr" rid="pcbi.1002189-Chou7">[56]</xref>. The MLR model established with the determined descriptors was:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.e001" xlink:type="simple"/></disp-formula></p>
        <p>The SVM model was also established with the five identified descriptors using libSVM.</p>
        <p>Correlation between the predicted and observed pIC<sub>50</sub> activities on EGFR ligands of known activity using the constructed MLR and SVM models were illustrated in <xref ref-type="fig" rid="pcbi-1002189-g003">Figure 3a and 3b</xref>, respectively. Correlation coefficients based on the training set were 0.7858 for the MLR model and 0.8754 for the SVM model. Activity predictions of Iressa® and the TCM candidates using MLR and SVM were summarized in <xref ref-type="table" rid="pcbi-1002189-t001">Table 1</xref>. Both models indicate that Iressa and the TCM candidates are compounds with acceptable predicted activities. Predicted activities (pIC<sub>50</sub>) of Iressa by the trained MLR and SVM models were 6.715 and 5.110, respectively. The Iressa activity predicted by SVM was closer to experimentally determined Iressa activities (pIC<sub>50</sub>) between 4.76–5.96 <xref ref-type="bibr" rid="pcbi.1002189-Pernas1">[57]</xref>, thus SVM values may be more accurate predictions of the actual activity.</p>
        <fig id="pcbi-1002189-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002189.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Correlation of observed and predicted activity (pIC<sub>50</sub>) using 2D-QSAR models.</title>
            <p>(A) MLR and (B) SVM.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.g003" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3c">
        <title>3D QSAR Model</title>
        <p>The results of CoMFA and CoMSIA model generation are detailed in <xref ref-type="table" rid="pcbi-1002189-t002">Table 2</xref>. Steric field was the sole factor in the CoMFA model since the electrostatic field value was zero. Cross-validated (q<sup>2</sup>) and non-cross-validated (r<sup>2</sup>) correlation coefficient values of 0.721 and 0.986, respectively, indicated a high level of confidence for this model. The small standard error of estimates (SEE) and large F-test value further supported the reliability of this model. In contrast, CoMSIA models were influenced by multiple factors including steric field, hydrophobic region, and hydrogen bond donor/acceptors. Among all generated versions of the CoMSIA model, CoMSIA_SHD had the highest r<sup>2</sup> (0.988), lowest SEE (0.133), and highest F value (134.272), thus was selected as the optimum CoMSIA model for use in this study. The pIC<sub>50</sub> of 20 ligands predicted by the constructed CoMFA and CoMSIA models were compared with observed pIC<sub>50</sub> reported by Fidanze et al. <xref ref-type="bibr" rid="pcbi.1002189-Fidanze1">[53]</xref> in <xref ref-type="table" rid="pcbi-1002189-t003">Table 3</xref>. In general, both models gave similar predicted values and were close to the experimentally determined activities. Correlations between predicted and observed pIC<sub>50</sub> using CoMFA and CoMSIA models are summarized in <xref ref-type="fig" rid="pcbi-1002189-g004">Figure 4a and 4b</xref>, respectively. High correlation coefficients validated the reliability of the constructed CoMFA (r<sup>2</sup> = 0.9860) and CoMSIA(r<sup>2</sup> = 0.9877) models.</p>
        <fig id="pcbi-1002189-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002189.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Correlation of observed and predicted activity (pIC<sub>50</sub>) using 3D-QSAR models.</title>
            <p>(A) CoMFA and (B) CoMSIA.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.g004" xlink:type="simple"/>
        </fig>
        <table-wrap id="pcbi-1002189-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1002189.t002</object-id><label>Table 2</label><caption>
            <title>CoMFA and CoMSIA models as a factor of various fractions and the corresponding validation values.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1002189-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.t002" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="2" rowspan="1">Cross validation</td>
                <td align="left" colspan="3" rowspan="1">Non-cross validation</td>
                <td align="left" colspan="4" rowspan="1">Fraction</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">ONC</td>
                <td align="left" colspan="1" rowspan="1">q<sup>2</sup><sub>cv</sub></td>
                <td align="left" colspan="1" rowspan="1">r<sup>2</sup></td>
                <td align="left" colspan="1" rowspan="1">SEE</td>
                <td align="left" colspan="1" rowspan="1">F</td>
                <td align="left" colspan="1" rowspan="1">S</td>
                <td align="left" colspan="1" rowspan="1">H</td>
                <td align="left" colspan="1" rowspan="1">D</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>CoMFA</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.721</td>
                <td align="left" colspan="1" rowspan="1">0.986</td>
                <td align="left" colspan="1" rowspan="1">0.142</td>
                <td align="left" colspan="1" rowspan="1">117.843</td>
                <td align="left" colspan="1" rowspan="1">1.00</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">-</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>CoMFA</bold>
                </td>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">S</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.764</td>
                <td align="left" colspan="1" rowspan="1">0.975</td>
                <td align="left" colspan="1" rowspan="1">0.189</td>
                <td align="left" colspan="1" rowspan="1">65.257</td>
                <td align="left" colspan="1" rowspan="1">1.00</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">-</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">H</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.331</td>
                <td align="left" colspan="1" rowspan="1">0.980</td>
                <td align="left" colspan="1" rowspan="1">0.168</td>
                <td align="left" colspan="1" rowspan="1">83.249</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">1.00</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">-</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">D</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.236</td>
                <td align="left" colspan="1" rowspan="1">0.945</td>
                <td align="left" colspan="1" rowspan="1">0.281</td>
                <td align="left" colspan="1" rowspan="1">28.780</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">1.00</td>
                <td align="left" colspan="1" rowspan="1"/>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">A</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">−0.344</td>
                <td align="left" colspan="1" rowspan="1">0.784</td>
                <td align="left" colspan="1" rowspan="1">0.558</td>
                <td align="left" colspan="1" rowspan="1">6.034</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">1.00</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">SH</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.541</td>
                <td align="left" colspan="1" rowspan="1">0.986</td>
                <td align="left" colspan="1" rowspan="1">0.141</td>
                <td align="left" colspan="1" rowspan="1">118.218</td>
                <td align="left" colspan="1" rowspan="1">0.37</td>
                <td align="left" colspan="1" rowspan="1">0.63</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">-</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">SD</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.615</td>
                <td align="left" colspan="1" rowspan="1">0.982</td>
                <td align="left" colspan="1" rowspan="1">0.159</td>
                <td align="left" colspan="1" rowspan="1">92.965</td>
                <td align="left" colspan="1" rowspan="1">0.48</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">0.52</td>
                <td align="left" colspan="1" rowspan="1">-</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">SA</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.718</td>
                <td align="left" colspan="1" rowspan="1">0.977</td>
                <td align="left" colspan="1" rowspan="1">0.180</td>
                <td align="left" colspan="1" rowspan="1">72.008</td>
                <td align="left" colspan="1" rowspan="1">0.53</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">0.47</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">HD</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.569</td>
                <td align="left" colspan="1" rowspan="1">0.982</td>
                <td align="left" colspan="1" rowspan="1">0.160</td>
                <td align="left" colspan="1" rowspan="1">91.804</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">0.56</td>
                <td align="left" colspan="1" rowspan="1">0.44</td>
                <td align="left" colspan="1" rowspan="1">-</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">HA</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.265</td>
                <td align="left" colspan="1" rowspan="1">0.979</td>
                <td align="left" colspan="1" rowspan="1">0.176</td>
                <td align="left" colspan="1" rowspan="1">76.040</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">0.60</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">0.40</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">DA</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.003</td>
                <td align="left" colspan="1" rowspan="1">0.956</td>
                <td align="left" colspan="1" rowspan="1">0.250</td>
                <td align="left" colspan="1" rowspan="1">36.635</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">0.60</td>
                <td align="left" colspan="1" rowspan="1">0.40</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">SHD<xref ref-type="table-fn" rid="nt110">*</xref></td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.662</td>
                <td align="left" colspan="1" rowspan="1">0.988</td>
                <td align="left" colspan="1" rowspan="1">0.133</td>
                <td align="left" colspan="1" rowspan="1">134.272</td>
                <td align="left" colspan="1" rowspan="1">0.26</td>
                <td align="left" colspan="1" rowspan="1">0.40</td>
                <td align="left" colspan="1" rowspan="1">0.35</td>
                <td align="left" colspan="1" rowspan="1">-</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">SHA</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.441</td>
                <td align="left" colspan="1" rowspan="1">0.983</td>
                <td align="left" colspan="1" rowspan="1">0.156</td>
                <td align="left" colspan="1" rowspan="1">96.519</td>
                <td align="left" colspan="1" rowspan="1">0.26</td>
                <td align="left" colspan="1" rowspan="1">0.42</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">0.33</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">SDA</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.664</td>
                <td align="left" colspan="1" rowspan="1">0.979</td>
                <td align="left" colspan="1" rowspan="1">0.173</td>
                <td align="left" colspan="1" rowspan="1">78.179</td>
                <td align="left" colspan="1" rowspan="1">0.33</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">0.38</td>
                <td align="left" colspan="1" rowspan="1">0.30</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">HDA</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.543</td>
                <td align="left" colspan="1" rowspan="1">0.979</td>
                <td align="left" colspan="1" rowspan="1">0.175</td>
                <td align="left" colspan="1" rowspan="1">76.649</td>
                <td align="left" colspan="1" rowspan="1">-</td>
                <td align="left" colspan="1" rowspan="1">0.42</td>
                <td align="left" colspan="1" rowspan="1">0.32</td>
                <td align="left" colspan="1" rowspan="1">0.26</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">SHDA</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.665</td>
                <td align="left" colspan="1" rowspan="1">0.985</td>
                <td align="left" colspan="1" rowspan="1">0.148</td>
                <td align="left" colspan="1" rowspan="1">107.106</td>
                <td align="left" colspan="1" rowspan="1">0.20</td>
                <td align="left" colspan="1" rowspan="1">0.31</td>
                <td align="left" colspan="1" rowspan="1">0.27</td>
                <td align="left" colspan="1" rowspan="1">0.22</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt102">
              <label/>
              <p>ONC: Optimal number of components.</p>
            </fn>
            <fn id="nt103">
              <label/>
              <p>SEE: Standard error of estimate.</p>
            </fn>
            <fn id="nt104">
              <label/>
              <p>F: F-test value.</p>
            </fn>
            <fn id="nt105">
              <label/>
              <p>PLS: partial least squares.</p>
            </fn>
            <fn id="nt106">
              <label/>
              <p>S: Steric.</p>
            </fn>
            <fn id="nt107">
              <label/>
              <p>H: Hydrophobic.</p>
            </fn>
            <fn id="nt108">
              <label/>
              <p>D: Hydrogen bond donor.</p>
            </fn>
            <fn id="nt109">
              <label/>
              <p>A: Hydrogen bond acceptor.</p>
            </fn>
            <fn id="nt110">
              <label/>
              <p>*: CoMISA model selected for 3D-QSAR simulation.</p>
            </fn>
          </table-wrap-foot></table-wrap>
        <table-wrap id="pcbi-1002189-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1002189.t003</object-id><label>Table 3</label><caption>
            <title>Observed and predicted activities of EGFR ligands using the constructed CoMFA and CoMSIA models.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1002189-t003-3" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.t003" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="2" rowspan="1">CoMFA</td>
                <td align="left" colspan="2" rowspan="1">CoMSIA</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Comp.</td>
                <td align="left" colspan="1" rowspan="1">Observed pIC<sub>50</sub><xref ref-type="table-fn" rid="nt111">*</xref></td>
                <td align="left" colspan="1" rowspan="1">PredictedpIC<sub>50</sub></td>
                <td align="left" colspan="1" rowspan="1">Residual</td>
                <td align="left" colspan="1" rowspan="1">PredictedpIC<sub>50</sub></td>
                <td align="left" colspan="1" rowspan="1">Residual</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">6.620</td>
                <td align="left" colspan="1" rowspan="1">6.571</td>
                <td align="left" colspan="1" rowspan="1">0.049</td>
                <td align="left" colspan="1" rowspan="1">6.600</td>
                <td align="left" colspan="1" rowspan="1">0.020</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">2</td>
                <td align="left" colspan="1" rowspan="1">7.081</td>
                <td align="left" colspan="1" rowspan="1">7.192</td>
                <td align="left" colspan="1" rowspan="1">−0.111</td>
                <td align="left" colspan="1" rowspan="1">7.230</td>
                <td align="left" colspan="1" rowspan="1">−0.149</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">7.260</td>
                <td align="left" colspan="1" rowspan="1">7.234</td>
                <td align="left" colspan="1" rowspan="1">0.026</td>
                <td align="left" colspan="1" rowspan="1">7.147</td>
                <td align="left" colspan="1" rowspan="1">0.113</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">4</td>
                <td align="left" colspan="1" rowspan="1">6.638</td>
                <td align="left" colspan="1" rowspan="1">6.394</td>
                <td align="left" colspan="1" rowspan="1">0.244</td>
                <td align="left" colspan="1" rowspan="1">6.522</td>
                <td align="left" colspan="1" rowspan="1">0.116</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">5</td>
                <td align="left" colspan="1" rowspan="1">8.102</td>
                <td align="left" colspan="1" rowspan="1">8.337</td>
                <td align="left" colspan="1" rowspan="1">−0.235</td>
                <td align="left" colspan="1" rowspan="1">8.275</td>
                <td align="left" colspan="1" rowspan="1">−0.173</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">8.721</td>
                <td align="left" colspan="1" rowspan="1">8.508</td>
                <td align="left" colspan="1" rowspan="1">0.213</td>
                <td align="left" colspan="1" rowspan="1">8.493</td>
                <td align="left" colspan="1" rowspan="1">0.228</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">7</td>
                <td align="left" colspan="1" rowspan="1">6.060</td>
                <td align="left" colspan="1" rowspan="1">5.940</td>
                <td align="left" colspan="1" rowspan="1">0.120</td>
                <td align="left" colspan="1" rowspan="1">6.012</td>
                <td align="left" colspan="1" rowspan="1">0.048</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">8</td>
                <td align="left" colspan="1" rowspan="1">6.180</td>
                <td align="left" colspan="1" rowspan="1">6.237</td>
                <td align="left" colspan="1" rowspan="1">−0.057</td>
                <td align="left" colspan="1" rowspan="1">6.247</td>
                <td align="left" colspan="1" rowspan="1">−0.067</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">9</td>
                <td align="left" colspan="1" rowspan="1">7.000</td>
                <td align="left" colspan="1" rowspan="1">6.893</td>
                <td align="left" colspan="1" rowspan="1">0.107</td>
                <td align="left" colspan="1" rowspan="1">6.952</td>
                <td align="left" colspan="1" rowspan="1">0.048</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">10</td>
                <td align="left" colspan="1" rowspan="1">6.721</td>
                <td align="left" colspan="1" rowspan="1">6.828</td>
                <td align="left" colspan="1" rowspan="1">−0.107</td>
                <td align="left" colspan="1" rowspan="1">6.717</td>
                <td align="left" colspan="1" rowspan="1">0.004</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">11</td>
                <td align="left" colspan="1" rowspan="1">7.201</td>
                <td align="left" colspan="1" rowspan="1">7.293</td>
                <td align="left" colspan="1" rowspan="1">−0.092</td>
                <td align="left" colspan="1" rowspan="1">7.322</td>
                <td align="left" colspan="1" rowspan="1">−0.121</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">12</td>
                <td align="left" colspan="1" rowspan="1">8.208</td>
                <td align="left" colspan="1" rowspan="1">8.149</td>
                <td align="left" colspan="1" rowspan="1">0.059</td>
                <td align="left" colspan="1" rowspan="1">7.806</td>
                <td align="left" colspan="1" rowspan="1">0.402</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">13</td>
                <td align="left" colspan="1" rowspan="1">9.108</td>
                <td align="left" colspan="1" rowspan="1">9.077</td>
                <td align="left" colspan="1" rowspan="1">0.031</td>
                <td align="left" colspan="1" rowspan="1">9.167</td>
                <td align="left" colspan="1" rowspan="1">−0.059</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">14</td>
                <td align="left" colspan="1" rowspan="1">9.018</td>
                <td align="left" colspan="1" rowspan="1">9.059</td>
                <td align="left" colspan="1" rowspan="1">−0.041</td>
                <td align="left" colspan="1" rowspan="1">9.023</td>
                <td align="left" colspan="1" rowspan="1">−0.005</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">15</td>
                <td align="left" colspan="1" rowspan="1">8.638</td>
                <td align="left" colspan="1" rowspan="1">8.563</td>
                <td align="left" colspan="1" rowspan="1">0.075</td>
                <td align="left" colspan="1" rowspan="1">8.566</td>
                <td align="left" colspan="1" rowspan="1">0.072</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">16</td>
                <td align="left" colspan="1" rowspan="1">7.252</td>
                <td align="left" colspan="1" rowspan="1">6.377</td>
                <td align="left" colspan="1" rowspan="1">0.875</td>
                <td align="left" colspan="1" rowspan="1">6.012</td>
                <td align="left" colspan="1" rowspan="1">1.240</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">17</td>
                <td align="left" colspan="1" rowspan="1">7.244</td>
                <td align="left" colspan="1" rowspan="1">7.210</td>
                <td align="left" colspan="1" rowspan="1">0.034</td>
                <td align="left" colspan="1" rowspan="1">7.159</td>
                <td align="left" colspan="1" rowspan="1">0.085</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">18</td>
                <td align="left" colspan="1" rowspan="1">7.796</td>
                <td align="left" colspan="1" rowspan="1">7.790</td>
                <td align="left" colspan="1" rowspan="1">0.006</td>
                <td align="left" colspan="1" rowspan="1">7.710</td>
                <td align="left" colspan="1" rowspan="1">0.086</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">19</td>
                <td align="left" colspan="1" rowspan="1">7.620</td>
                <td align="left" colspan="1" rowspan="1">7.744</td>
                <td align="left" colspan="1" rowspan="1">−0.124</td>
                <td align="left" colspan="1" rowspan="1">7.729</td>
                <td align="left" colspan="1" rowspan="1">−0.109</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">20</td>
                <td align="left" colspan="1" rowspan="1">8.194</td>
                <td align="left" colspan="1" rowspan="1">8.089</td>
                <td align="left" colspan="1" rowspan="1">0.105</td>
                <td align="left" colspan="1" rowspan="1">8.216</td>
                <td align="left" colspan="1" rowspan="1">−0.022</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt111">
              <label/>
              <p>*: Experimental values of ligand bioactivity adapted from Ref <xref ref-type="bibr" rid="pcbi.1002189-Fidanze1">[53]</xref>.</p>
            </fn>
          </table-wrap-foot></table-wrap>
        <p>Ligand activities of Iressa® and the TCM candidates can be predicted based on structural conformation to the 3D-QSAR feature map, including features in steric field, hydrophobic field, and H-bond donor/acceptor characteristics. As illustrated in <xref ref-type="fig" rid="pcbi-1002189-g005">Figure 5</xref>, Iressa and the TCM candidates were able to match the generated 3D-QSAR model features. The benzene in Iressa® favored steric and hydrophobic fields, and H-bond was favored between its amine group and Asp855. In 2-O-Caffeoyl tartaric acid, the benzene structure favored steric and hydrophobic fields, and the carboxyl group favored H-bond formation with Lys716 and Lys728. The carbon chain structure in Emetine contoured to the steric and hydrophobic fields, and the amine group favored H-bond formation with Asp855. Rosmaricine had benzene and isopropyl structures that favored steric and hydrophobic fields, and an amine group that favored H-bond with Asp 855. The benzene structure in 2-O-feruloyl tartaric acid favored steric fields and the carboxyl group favored H-bond formations with Lys716 and Lys728. Iressa® and the TCM candidates have structural components that contour to the features of the 3D-QSAR model, thus were likely to be biologically active.</p>
        <fig id="pcbi-1002189-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002189.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>Structural contouring of different compounds to 3D-QSAR mapping.</title>
            <p>(A) Iressa, (B) 2-O-Caffeoyl tartaric acid, (C) Emetine, (D) Rosmaricine, and (E) 2-O-Feruloyl tartaric acid. 3D-QSAR features are represented by the following: steric field favor/disfavor (green/yellow), hydrophobic field favor/disfavor (cyan/white), and hydrogen bond donor avor/disfavor (magenta/orange). Bond distances are shown in yellow.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.g005" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3d">
        <title>Molecular Dynamics Simulation</title>
        <p>Binding stability of the control and TCM candidates was validated using MD simulation. RMSDs of protein-ligand complex (<xref ref-type="fig" rid="pcbi-1002189-g006">Figure 6a</xref>) and individual ligand (<xref ref-type="fig" rid="pcbi-1002189-g006">Figure 6b</xref>) stabilized after 10 ns. The RMSDs of the protein-ligand complexes stabilized at approximately 1.6Å. With regard to individual ligands, the RMSDs of Iressa and 2-O-caffeoyl tartaric acid was 2.0 and 1.6Å, respectively. All other compounds registered RMSD values of approximately 1.0Å. The lower RMSD values of the TCM candidates suggest more stability within the receptor compared to Iressa. The energy trajectory of each compound is shown in <xref ref-type="fig" rid="pcbi-1002189-g006">Figure 6c</xref>. Complexes formed by Rosmaricine and 2-O-feruloyl tartaric acid had the lowest total energy (&lt;−14,800 kcal/mol), followed by Iressa® and Emetine (approximately −14,700 kcal/mol), and 2-O-caffeoyl tartaric acid (−14,600 kcal/mol). Stabilization of total energy in ligand-protein complexes was achieved after 12 ns.</p>
        <fig id="pcbi-1002189-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002189.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>RMSD and total energy during MD simulation.</title>
            <p>(A) Protein-ligand complex RMSD (Å), (B) ligand RMSD (Å) and (C) total energy of protein-ligand complex.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.g006" xlink:type="simple"/>
        </fig>
        <p>H-bond distance profiles in the EGFR receptor were summarized in <xref ref-type="fig" rid="pcbi-1002189-g007">Figure 7</xref>. A single H-bond between the amine group on Iressa® and the carboxyl group on Asp855 was formed after 9.74 ns and stabilized after 20 ns (<xref ref-type="fig" rid="pcbi-1002189-g007">Figure 7a</xref>). Two H-bonds were formed between the carboxyl group of 2-O-caffeoyl tartaric acid and Lys716 and Lys728 of the EGFR receptor (<xref ref-type="fig" rid="pcbi-1002189-g007">Figure 7b</xref>). The formation of two H-bonds contributed to a higher stability between 2-O-caffeoyl tartaric acid and the EGFR receptor. However, an increase in H-bond distance was observed towards the end of the 20 ns simulation period, suggesting a weakening of the H-bond at Lys728. Emetine formed a total of four H-bonds with the receptor, two with Asp722 and two with Ala855 (<xref ref-type="fig" rid="pcbi-1002189-g007">Figure 7c</xref>). Bond distances stabilized after 10 ns for Ala722 and 4 ns for Asp855. Rosmaricine formed three H-bonds each at Asp841 and Arg855 (<xref ref-type="fig" rid="pcbi-1002189-g007">Figure 7d</xref>). The multiple H-bonds enabled Rosmaricine to remain in a stable state within the protein. 2-O-Feruloyl tartaric acid also formed multiple H-bond at Lys716 and Lys728, enhancing its stability within the receptor site (<xref ref-type="fig" rid="pcbi-1002189-g007">Figure 7e</xref>). However, similar to 2-O-caffeoyl tartaric acid, an increase in H-bond distance was also observed at Lys728 for 2-O-feruloyl tartaric acid. These observations suggest that the bond at Lys728 weakens throughout the MD simulation process, and that the H-bond at Lys716 may be the primary bond for 2-O-caffeoyl tartaric acid and 2-O-feruloyl tartaric acid. In addition, periodic fluctuations in H-bond distances were observed in 2-O-caffeoyl tartaric acid, Rosmaricine, and 2-O-feruloyl tartaric acid. These phenomena can be attributed to the rotation of the amine group where the H-bond is formed. These MD results support our docking findings which identify Asp855, Lys716, and Lys 728 as key residues for docking.</p>
        <fig id="pcbi-1002189-g007" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002189.g007</object-id>
          <label>Figure 7</label>
          <caption>
            <title>Hydrogen bond distance profile during MD simulation.</title>
            <p>(A) Iressa, (B) 2-O-Caffeoyl tartaric acid, (C) Emetine, (D) Rosmaricine, (E) 2-O-Feruloyl tartaric acid.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.g007" xlink:type="simple"/>
        </fig>
        <p>As determined in the CoMSIA model, hydrophobic interactions were key factors contributing to ligand bioactivity. Toward the final 20 ns of analysis, hydrophobic amino acids surrounding the docking region were Leu718, Val726, Ala743, Cys775, Phe795, Cys797, and Leu844. The hydrophobic subgroups of Iressa®, Emetine, and Rosmaricine were surrounded by Val726, Cys797, and Leu844 (<xref ref-type="fig" rid="pcbi-1002189-g008">Figure 8a</xref>). Hydrophobic groups of 2-O-caffeoyl tartaric acid were also surrounded Val726, Cys797, and Leu844 (<xref ref-type="fig" rid="pcbi-1002189-g008">Figure 8b</xref>). The hydrophobic region of 2-O-feruloyl tartaric acid was attracted to the Phe795 on EGFR (<xref ref-type="fig" rid="pcbi-1002189-g008">Figure 8b</xref>). The significance of matching the hydrophobic region of the ligand to that of the receptor may be to increase stability of the ligand-protein complex, and contribute to the bioactivity of the activated ligand. Our results indicate that Iressa® and the TCM candidates remained stable within the EFGR hydrophobic area following MD simulations.</p>
        <fig id="pcbi-1002189-g008" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002189.g008</object-id>
          <label>Figure 8</label>
          <caption>
            <title>Hydrophobic interactions of different compounds in EGFR.</title>
            <p>(A) Iressa (orange), Emetine (green), and Rosmaricine (violet) (B) 2-O-Caffeoyl tartaric acid (blue), and 2-O-feruloyl tartaric acid (green). The hydrophobic regions in the binding site are depicted in red, and specific hydrophobic amino acids close to TCM compounds are indicated in red.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.g008" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3e">
        <title>Conclusion</title>
        <p>Structural and ligand based methods supported 2-O-caffeoyl tartaric acid, Emetine, Rosmaricine, and 2-O-feruloyl tartaric acid as potential EGFR inhibitors. Structurally, the TCM candidates were capable of forming H-bonds with key residues Asp855, Lys716, and Lys728 and matched hydrophobic regions of the receptor. Bioactivity of the candidates were evaluated using validated MLR, SVM, CoMFA, and CoMSIA models. All models indicated that the TCM candidates have good predicted bioactivity. Molecular simulation results further supported the high potential for the TCM candidates in drug development. Iressa®, the drug currently used clinically, bound to the ERGF receptor through a single H-bond at Asp855. In comparison, multiple H-bonds formed at Asp855 and additional H-bonds formed at Ala722 and Arg841 increase the stability of Emetine and Rosmaricine, respectively. The ability of carboxyl groups in 2-O-caffeoyl tartaric acid and 2-O-feruloyl tartaric acid to form multiple H-bond networks that directly blocked the ATP binding site was also a unique characteristic worthwhile of further investigation. Contour to hydrophobic regions of the TCM candidates within the receptor site provides additional support for the stability of the protein-ligand complex. In summary, using different simulation and validation methods, we have identified four TCM compounds that may have potential as novel EGFR inhibitors. As the four TCM compounds have two distinctive types of binding locations and bond formation within the EGFR binding site, we suggest exploring the possibility of connecting Emetine/Rosmaricine with 2-O-caffeoyl tartaric acid/2-O-feruloyl tartaric acid through a spacer. The connection could allow more of points of attachment, which in turn would contribute to more stable binding within the tyrosine kinase site.</p>
      </sec>
    </sec>
    <sec id="s4">
      <title>Supporting Information</title>
      <supplementary-material id="pcbi.1002189.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002189.s001" xlink:type="simple">
        <label>Table S1</label>
        <caption>
          <p><bold>Molecular structures and biological activities of ligands used for model training.</bold> Structural details of the 20 ligands adopted for ligand-based studies are listed within this table. Experimental bioactivity values for each ligand were adapted from Ref <xref ref-type="bibr" rid="pcbi.1002189-Fidanze1">[53]</xref>.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We are grateful to the Asia University cloud-computing facilities.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pcbi.1002189-deOliveira1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>de Oliveira</surname><given-names>AN</given-names></name><name name-style="western"><surname>Bocca</surname><given-names>CC</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>JE</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>AL</given-names></name><name name-style="western"><surname>Silva</surname><given-names>TP</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>New substituted 4-arylaminoquinazolines as potent inhibitors of breast tumor cell lines: <italic>in vitro</italic> and docking experiments.</article-title>             <source>Eur J Med Chem</source>             <volume>45</volume>             <fpage>4339</fpage>             <lpage>4342</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-ElAzab1">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>El-Azab</surname><given-names>AS</given-names></name><name name-style="western"><surname>Al-Omar</surname><given-names>MA</given-names></name><name name-style="western"><surname>Abdel-Aziz</surname><given-names>AA</given-names></name><name name-style="western"><surname>Abdel-Aziz</surname><given-names>NI</given-names></name><name name-style="western"><surname>el-Sayed</surname><given-names>MA</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study.</article-title>             <source>Eur J Med Chem</source>             <volume>45</volume>             <fpage>4188</fpage>             <lpage>4198</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Wang1">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Prediction of antimicrobial peptides based on sequence alignment and feature selection methods.</article-title>             <source>PLoS One</source>             <volume>6</volume>             <fpage>e18476</fpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Herbst1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Herbst</surname><given-names>RS</given-names></name></person-group>             <year>2004</year>             <article-title>Review of epidermal growth factor receptor biology.</article-title>             <source>Int J Radiat Oncol Biol Phys</source>             <volume>59</volume>             <fpage>21</fpage>             <lpage>26</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Oda1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Oda</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Funahashi</surname><given-names>A</given-names></name><name name-style="western"><surname>Kitano</surname><given-names>H</given-names></name></person-group>             <year>2005</year>             <article-title>A comprehensive pathway map of epidermal growth factor receptor signaling.</article-title>             <source>Mol Syst Biol</source>             <volume>1</volume>             <fpage>1</fpage>             <lpage>17</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Franklin1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Franklin</surname><given-names>WA</given-names></name><name name-style="western"><surname>Veve</surname><given-names>R</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>FR</given-names></name><name name-style="western"><surname>Helfrich</surname><given-names>BA</given-names></name><name name-style="western"><surname>Bunn</surname><given-names>PA</given-names><suffix>Jr</suffix></name></person-group>             <year>2002</year>             <article-title>Epidermal growth factor receptor family in lung cancer and premalignancy.</article-title>             <source>Semin Oncol</source>             <volume>29</volume>             <fpage>3</fpage>             <lpage>14</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Linggi1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Linggi</surname><given-names>B</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>G</given-names></name></person-group>             <year>2006</year>             <article-title>ErbB receptors: new insights on mechanisms and biology.</article-title>             <source>Trends Cell Biol</source>             <volume>16</volume>             <fpage>649</fpage>             <lpage>656</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Chan1">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>TO</given-names></name><name name-style="western"><surname>Rittenhouse</surname><given-names>SE</given-names></name><name name-style="western"><surname>Tsichlis</surname><given-names>PN</given-names></name></person-group>             <year>1999</year>             <article-title>AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation.</article-title>             <source>Ann Rev Biochem</source>             <volume>68</volume>             <fpage>965</fpage>             <lpage>1014</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Either1">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Either</surname><given-names>SP</given-names></name></person-group>             <year>2002</year>             <article-title>Signal transduction pathways: the molecular basis for targeted therapies.</article-title>             <source>Semin Radiat Oncol</source>             <volume>12</volume>             <fpage>3</fpage>             <lpage>10</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Shibata1">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Shibata</surname><given-names>T</given-names></name><name name-style="western"><surname>Kawano</surname><given-names>T</given-names></name><name name-style="western"><surname>Nagayasu</surname><given-names>H</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>K</given-names></name><name name-style="western"><surname>Arisue</surname><given-names>M</given-names></name><etal/></person-group>             <year>1996</year>             <article-title>Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth.</article-title>             <source>Tumour Biol</source>             <volume>17</volume>             <fpage>168</fpage>             <lpage>175</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Petit1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Petit</surname><given-names>AM</given-names></name><name name-style="western"><surname>Rak</surname><given-names>J</given-names></name><name name-style="western"><surname>Hung</surname><given-names>MC</given-names></name><name name-style="western"><surname>Rockwell</surname><given-names>P</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>N</given-names></name><etal/></person-group>             <year>1997</year>             <article-title>Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.</article-title>             <source>Am J Pathol</source>             <volume>151</volume>             <fpage>1523</fpage>             <lpage>1530</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Mitsudomi1">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mitsudomi</surname><given-names>T</given-names></name><name name-style="western"><surname>Yatabe</surname><given-names>Y</given-names></name></person-group>             <year>2010</year>             <article-title>Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.</article-title>             <source>FEBS J:</source>             <volume>277</volume>             <fpage>301</fpage>             <lpage>308</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Sordella1">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sordella</surname><given-names>R</given-names></name><name name-style="western"><surname>Bell</surname><given-names>DW</given-names></name><name name-style="western"><surname>Haber</surname><given-names>DA</given-names></name><name name-style="western"><surname>Settleman</surname><given-names>J</given-names></name></person-group>             <year>2004</year>             <article-title>Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.</article-title>             <source>Science</source>             <volume>305</volume>             <fpage>1163</fpage>             <lpage>1167</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Wakeling1">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wakeling</surname><given-names>AE</given-names></name><name name-style="western"><surname>Barker</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Davies</surname><given-names>DH</given-names></name><name name-style="western"><surname>Brown</surname><given-names>DS</given-names></name><name name-style="western"><surname>Green</surname><given-names>LR</given-names></name><etal/></person-group>             <year>1996</year>             <article-title>Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.</article-title>             <source>Breast Cancer Res Treat</source>             <volume>38</volume>             <fpage>67</fpage>             <lpage>73</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Merlo1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Merlo</surname><given-names>V</given-names></name><name name-style="western"><surname>Longo</surname><given-names>M</given-names></name><name name-style="western"><surname>Novello</surname><given-names>S</given-names></name><name name-style="western"><surname>Scagliotti</surname><given-names>GV</given-names></name></person-group>             <year>2011</year>             <article-title>EGFR pathway in advanced non-small cell lung cancer.</article-title>             <source>Front Biosci</source>             <volume>3</volume>             <fpage>501</fpage>             <lpage>517</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-VandenEynde1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Van den Eynde</surname><given-names>M</given-names></name><name name-style="western"><surname>Baurain</surname><given-names>JF</given-names></name><name name-style="western"><surname>Mazzeo</surname><given-names>F</given-names></name><name name-style="western"><surname>Machiels</surname><given-names>JP</given-names></name></person-group>             <year>2011</year>             <article-title>Epidermal growth factor receptor targeted therapies for solid tumours.</article-title>             <source>Acta Clin Belg</source>             <volume>66</volume>             <fpage>10</fpage>             <lpage>17</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Sherman1">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sherman</surname><given-names>SI</given-names></name></person-group>             <year>2011</year>             <article-title>Targeted therapies for thyroid tumors.</article-title>             <source>Mod Pathol</source>             <volume>24</volume>             <fpage>S44</fpage>             <lpage>52</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Medina1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Medina</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Goodin</surname><given-names>S</given-names></name></person-group>             <year>2008</year>             <article-title>Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.</article-title>             <source>Clin Ther</source>             <volume>30</volume>             <fpage>1426</fpage>             <lpage>1447</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Johnston1">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>SR</given-names></name><name name-style="western"><surname>Leary</surname><given-names>A</given-names></name></person-group>             <year>2006</year>             <article-title>Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.</article-title>             <source>Drugs Today (Barc)</source>             <volume>42</volume>             <fpage>441</fpage>             <lpage>453</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Forsythe1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Forsythe</surname><given-names>B</given-names></name><name name-style="western"><surname>Faulkner</surname><given-names>K</given-names></name></person-group>             <year>2004</year>             <article-title>Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer.</article-title>             <source>Drug Saf</source>             <volume>27</volume>             <fpage>1081</fpage>             <lpage>1092</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-AustraZeneca1">
        <label>21</label>
        <element-citation publication-type="other" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>AustraZeneca</surname><given-names>Pharmaceuticals</given-names></name></person-group>             <year>2011</year>             <comment>Iressa Product Information. Available: <ext-link ext-link-type="uri" xlink:href="http://www.iressa.com/product-information" xlink:type="simple">http://www.iressa.com/product-information</ext-link>. Accessed 15 May 2011</comment>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Chen1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T</given-names></name><name name-style="western"><surname>Shi</surname><given-names>XH</given-names></name><name name-style="western"><surname>Cai</surname><given-names>YD</given-names></name><name name-style="western"><surname>Chou</surname><given-names>KC</given-names></name></person-group>             <year>2010</year>             <article-title>Analysis of protein pathway networks using hybrid properties.</article-title>             <source>Molecules</source>             <volume>15</volume>             <fpage>8177</fpage>             <lpage>8192</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Huang1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>T</given-names></name><name name-style="western"><surname>Shi</surname><given-names>XH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><name name-style="western"><surname>Feng</surname><given-names>KY</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Analysis and prediction of the metabolic stability of proteins based on their sequential features, subcellular locations and interaction networks.</article-title>             <source>PLoS One</source>             <volume>5</volume>             <fpage>e10972</fpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Chou1">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>KC</given-names></name></person-group>             <year>1996</year>             <article-title>Review: Prediction of HIV protease cleavage sites in proteins.</article-title>             <source>Anal Biochem</source>             <volume>233</volume>             <fpage>1</fpage>             <lpage>14</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Chou2">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>KC</given-names></name></person-group>             <year>2001</year>             <article-title>Prediction of protein cellular attributes using pseudo-amino acid composition.</article-title>             <source>Proteins</source>             <volume>43</volume>             <fpage>246</fpage>             <lpage>255</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Shen1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>HB</given-names></name><name name-style="western"><surname>Chou</surname><given-names>KC</given-names></name></person-group>             <year>2008</year>             <article-title>HIVcleave: a web-server for predicting HIV protease cleavage sites in proteins.</article-title>             <source>Anal Biochem</source>             <volume>375</volume>             <fpage>388</fpage>             <lpage>390</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Chou3">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>KC</given-names></name><name name-style="western"><surname>Wu</surname><given-names>ZC</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X</given-names></name></person-group>             <year>2011</year>             <article-title>iLoc-Euk: A multi-label classifier for predicting the subcellular localization of singleplex and multiplex eukaryotic proteins.</article-title>             <source>PLoS One</source>             <volume>6</volume>             <fpage>e18258</fpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Chou4">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>KC</given-names></name></person-group>             <year>2004</year>             <article-title>Structural bioinformatics and its impact to biomedical science.</article-title>             <source>Curr Med Chem</source>             <volume>11</volume>             <fpage>2105</fpage>             <lpage>2134</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Chou5">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>KC</given-names></name><name name-style="western"><surname>Shen</surname><given-names>HB</given-names></name></person-group>             <year>2009</year>             <article-title>Review: Recent advances in developing web-servers for predicting protein attributes.</article-title>             <source>Nat Sci</source>             <volume>2</volume>             <fpage>63</fpage>             <lpage>92</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Liao1">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>QH</given-names></name><name name-style="western"><surname>Gao</surname><given-names>QZ</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Chou</surname><given-names>KC</given-names></name></person-group>             <year>2011</year>             <article-title>Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR).</article-title>             <source>Med Chem</source>             <volume>7</volume>             <fpage>24</fpage>             <lpage>31</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Mustafa1">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mustafa</surname><given-names>M</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>A</given-names></name><name name-style="western"><surname>Kannan</surname><given-names>N</given-names></name></person-group>             <year>2011</year>             <article-title>Conformational regulation of the EGFR kinase core by the juxtamembrane and C-terminal tail: a molecular dynamics study.</article-title>             <source>Proteins</source>             <volume>79</volume>             <fpage>99</fpage>             <lpage>114</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Krug1">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Krug</surname><given-names>M</given-names></name><name name-style="western"><surname>Wichapong</surname><given-names>K</given-names></name><name name-style="western"><surname>Erlenkamp</surname><given-names>G</given-names></name><name name-style="western"><surname>Sippl</surname><given-names>W</given-names></name><name name-style="western"><surname>Schachtele</surname><given-names>C</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Discovery of 4-benzylamino-substituted alpha-carbolines as a novel class of receptor tyrosine kinase inhibitors.</article-title>             <source>ChemMedChem</source>             <volume>6</volume>             <fpage>63</fpage>             <lpage>72</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Zheng1">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xue</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Ji</surname><given-names>M</given-names></name></person-group>             <year>2010</year>             <article-title>Design, synthesis, docking and antitumor activity of quinazolino [3, 4-a] thieno [3, 2-d] pyrimidin-8-one derivatives.</article-title>             <source>Chem Biol Drug Des</source>             <volume>76</volume>             <fpage>285</fpage>             <lpage>290</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Qian1">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Synthesis, molecular modeling, and biological evaluation of cinnamic acid metronidazole ester derivatives as novel anticancer agents.</article-title>             <source>Bioorg Med Chem</source>             <volume>18</volume>             <fpage>4991</fpage>             <lpage>4996</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Lv1">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>PC</given-names></name><name name-style="western"><surname>Li</surname><given-names>HQ</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>HL</given-names></name></person-group>             <year>2010</year>             <article-title>Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton as anticancer agents.</article-title>             <source>Bioorg Med Chem</source>             <volume>18</volume>             <fpage>4606</fpage>             <lpage>4614</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Ali1">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>HI</given-names></name><name name-style="western"><surname>Nagamatsu</surname><given-names>T</given-names></name><name name-style="western"><surname>Akaho</surname><given-names>E</given-names></name></person-group>             <year>2011</year>             <article-title>Structure-based drug design and AutoDock study of potential protein tyrosine kinase inhibitors.</article-title>             <source>Bioinformation</source>             <volume>5</volume>             <fpage>368</fpage>             <lpage>374</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Nandi1">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nandi</surname><given-names>S</given-names></name><name name-style="western"><surname>Bagchi</surname><given-names>MC</given-names></name></person-group>             <year>2010</year>             <article-title>3D-QSAR and molecular docking studies of 4-anilinoquinazoline derivatives: a rational approach to anticancer drug design.</article-title>             <source>Mol Divers</source>             <volume>14</volume>             <fpage>27</fpage>             <lpage>38</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Cheng1">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>WY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>SL</given-names></name><name name-style="western"><surname>Hsiang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Li</surname><given-names>CC</given-names></name><name name-style="western"><surname>Lai</surname><given-names>TY</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Relationship between San-Huang-Xie-Xin-Tang and its herbal components on the gene expression profiles in HepG2 cells.</article-title>             <source>Am J Chin Med</source>             <volume>36</volume>             <fpage>783</fpage>             <lpage>797</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Liu1">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>SH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YF</given-names></name><name name-style="western"><surname>Liou</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YL</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>YC</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Mortality and cancer incidence among physicians of traditional Chinese medicine: a 20-year national follow-up study.</article-title>             <source>Occup Environ Med</source>             <volume>67</volume>             <fpage>166</fpage>             <lpage>169</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Hsu1">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>CH</given-names></name><name name-style="western"><surname>Yu</surname><given-names>MC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>TC</given-names></name><name name-style="western"><surname>Yang</surname><given-names>SY</given-names></name></person-group>             <year>2003</year>             <article-title>High eosinophil cationic protein level in asthmatic patients with "heat" Zheng.</article-title>             <source>Am J Chin Med</source>             <volume>31</volume>             <fpage>277</fpage>             <lpage>283</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Huang2">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Yu</surname><given-names>HW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>CH</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Structure-based and ligand-based drug design for HER2 receptor.</article-title>             <source>J Biomol Struct Dyn</source>             <volume>28</volume>             <fpage>23</fpage>             <lpage>37</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Chen2">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CYC</given-names></name></person-group>             <year>2010</year>             <article-title>Insights into designing the dual-targeted HER2/HSP90 inhibitors.</article-title>             <source>J Mol Graph Model</source>             <volume>29</volume>             <fpage>21</fpage>             <lpage>31</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Choowongkomon1">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Choowongkomon</surname><given-names>K</given-names></name><name name-style="western"><surname>Sawatdichaikul</surname><given-names>O</given-names></name><name name-style="western"><surname>Songtawee</surname><given-names>N</given-names></name><name name-style="western"><surname>Limtrakul</surname><given-names>J</given-names></name></person-group>             <year>2010</year>             <article-title>Receptor-based virtual screening of EGFR kinase inhibitors from the NCI diversity database.</article-title>             <source>Molecules</source>             <volume>15</volume>             <fpage>4041</fpage>             <lpage>4054</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-AbouSeri1">
        <label>44</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Abou-Seri</surname><given-names>SM</given-names></name></person-group>             <year>2010</year>             <article-title>Synthesis and biological evaluation of novel 2,4′-bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors.</article-title>             <source>Eur J Med Chem</source>             <volume>45</volume>             <fpage>4113</fpage>             <lpage>4121</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Pasha1">
        <label>45</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pasha</surname><given-names>FA</given-names></name><name name-style="western"><surname>Muddassar</surname><given-names>M</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>AK</given-names></name><name name-style="western"><surname>Cho</surname><given-names>SJ</given-names></name></person-group>             <year>2010</year>             <article-title>In silico QSAR studies of anilinoquinolines as EGFR inhibitors.</article-title>             <source>J Mol Model</source>             <volume>16</volume>             <fpage>263</fpage>             <lpage>277</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Coumar1">
        <label>46</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Coumar</surname><given-names>MS</given-names></name><name name-style="western"><surname>Chu</surname><given-names>CY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CW</given-names></name><name name-style="western"><surname>Shiao</surname><given-names>HY</given-names></name><name name-style="western"><surname>Ho</surname><given-names>YL</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.</article-title>             <source>J Med Chem</source>             <volume>53</volume>             <fpage>4980</fpage>             <lpage>4988</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Konkimalla1">
        <label>47</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Konkimalla</surname><given-names>VB</given-names></name><name name-style="western"><surname>Efferth</surname><given-names>T</given-names></name></person-group>             <year>2010</year>             <article-title>Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate.</article-title>             <source>Biochem Pharmacol</source>             <volume>80</volume>             <fpage>39</fpage>             <lpage>49</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Chen3">
        <label>48</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CYC</given-names></name></person-group>             <year>2011</year>             <article-title>TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico. </article-title>             <source>PLoS One</source>             <volume>6</volume>             <fpage>e15939</fpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Chou6">
        <label>49</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>KC</given-names></name></person-group>             <year>2011</year>             <article-title>Some remarks on protein attribute prediction and pseudo amino acid composition.</article-title>             <source>J Theor Biol</source>             <volume>273</volume>             <fpage>236</fpage>             <lpage>247</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-TheUniProt1">
        <label>50</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>The UniProt</surname><given-names>Consortium</given-names></name></person-group>             <year>2010</year>             <article-title>Ongoing and future developments at the Universal Protein Resource.</article-title>             <source>Nucleic Acids Res</source>             <volume>39</volume>             <fpage>D214</fpage>             <lpage>D219</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Yun1">
        <label>51</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Yun</surname><given-names>CH</given-names></name><name name-style="western"><surname>Boggon</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Woo</surname><given-names>MS</given-names></name><name name-style="western"><surname>Greulich</surname><given-names>H</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.</article-title>             <source>Cancer Cell</source>             <volume>11</volume>             <fpage>217</fpage>             <lpage>227</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Brooks1">
        <label>52</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>BR</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>CL</given-names></name><name name-style="western"><surname>Mackerell</surname><given-names>AD</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>L</given-names></name><name name-style="western"><surname>Petrella</surname><given-names>RJ</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>CHARMM: the biomolecular simulation program.</article-title>             <source>J Comput Chem</source>             <volume>30</volume>             <fpage>1545</fpage>             <lpage>1614</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Fidanze1">
        <label>53</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Fidanze</surname><given-names>SD</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>SA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>GT</given-names></name><name name-style="western"><surname>Mantei</surname><given-names>R</given-names></name><name name-style="western"><surname>Clark</surname><given-names>RF</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.</article-title>             <source>Bioorg Med Chem Lett</source>             <volume>20</volume>             <fpage>2452</fpage>             <lpage>2455</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Picard1">
        <label>54</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Picard</surname><given-names>RR</given-names></name><name name-style="western"><surname>Cook</surname><given-names>RD</given-names></name></person-group>             <year>1984</year>             <article-title>Cross-validation of regression models.</article-title>             <source>J Am Stat Assoc</source>             <volume>79</volume>             <fpage>575</fpage>             <lpage>583</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Fan1">
        <label>55</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>RE</given-names></name><name name-style="western"><surname>Chen</surname><given-names>PH</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CJ</given-names></name></person-group>             <year>2005</year>             <article-title>Working set selection using second order information for training support vector machines.</article-title>             <source>J Mach Learn Res</source>             <volume>6</volume>             <fpage>1889</fpage>             <lpage>1918</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Chou7">
        <label>56</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>KC</given-names></name><name name-style="western"><surname>Shen</surname><given-names>HB</given-names></name></person-group>             <year>2007</year>             <article-title>Review: Recent progresses in protein subcellular location prediction.</article-title>             <source>Anal Biochem</source>             <volume>370</volume>             <fpage>1</fpage>             <lpage>16</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002189-Pernas1">
        <label>57</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pernas</surname><given-names>FG</given-names></name><name name-style="western"><surname>Allen</surname><given-names>CT</given-names></name><name name-style="western"><surname>Winters</surname><given-names>ME</given-names></name><name name-style="western"><surname>Yan</surname><given-names>B</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>J</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer.</article-title>             <source>Clin Cancer Res</source>             <volume>15</volume>             <fpage>2361</fpage>             <lpage>2372</lpage>          </element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>